A phase I study of intravesical continuous perfusion of recombinant interleukin-2 in patients with superficial bladder cancer

A Phase I study was started to evaluate the locoregional and/or systemic toxic effects of the continuous perfusion of recombinant interleukin-2 (rIL-2) in superficial bladder cancer. Three different dose levels were used: 3 x 10(6) IU/day (3 patients), 9 x 10(6) IU/day (3 patients) and 27 x 10(6) IU...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of clinical oncology Vol. 18; no. 2; p. 100
Main Authors:	Ferlazzo, G, Magno, C, Lupo, G, Rizzo, M, Iemmo, R, Semino, C, Melioli, G
Format:	Journal Article
Language:	English
Published:	United States 01-04-1995
Subjects:	Administration, Intravesical Aged Disease-Free Survival Drug Administration Schedule Follow-Up Studies Hematuria - chemically induced HLA-DR Antigens - analysis Humans Hypotension - chemically induced Interleukin-2 - administration & dosage Interleukin-2 - adverse effects Leukocyte Count - drug effects Male Middle Aged Neoplasm Recurrence, Local Receptors, Interleukin-2 - analysis Recombinant Proteins - administration & dosage Recombinant Proteins - adverse effects T-Lymphocytes - drug effects T-Lymphocytes - immunology Urinary Bladder Neoplasms - immunology Urinary Bladder Neoplasms - therapy Urinary Bladder Neoplasms - urine Urine - cytology
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!